Medical Enterprises Europe B.V.
Mitomycin C (MMC)(Medical Enterprises Europe B.V.)은 Urinary Bladder Neoplasms 표적 치료제로, Non-Muscle-Invasive Bladder Cancer (NMIBC) 영역에서 개발·상용화 중입니다. 작용기전: inhibits jejunal MMC activity via OTR-dependent mechanisms with partial involvement of GLP-1R signaling but not NO pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 68건의 관련 임상이 등록되어 있습니다. 차별점: novel technique of integrating DRG stimulation using Direct Visual Placement with open lumbar or lumbosacral decompression an.
Urinary Bladder Neoplasms
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Recruiting
oncolytic virus (oHSV-GFP), each assessed using confocal microscopy a
linker governs the organelle targeting of TPP⁺-modified zinc phthalocyanine pho
novel technique of integrating DRG stimulation using Direct Visual Placement with open lumbar or lumbosacral decompression an
inhibits jejunal MMC activity via OTR-dependent mechanisms with partial involvement of GLP-1R signaling but not NO pathway
cytokine release, and suppresses neuroinflammation-associated transcriptional signatures specifically in microglia,
apoptosis and energy metabolism
biomarkers
escape, and enhanced mitochondrial dysfunction
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Medical Enterprises Europe B.V.
Mitomycin C (MMC)(Medical Enterprises Europe B.V.)은 Urinary Bladder Neoplasms 표적 치료제로, Non-Muscle-Invasive Bladder Cancer (NMIBC) 영역에서 개발·상용화 중입니다. 작용기전: inhibits jejunal MMC activity via OTR-dependent mechanisms with partial involvement of GLP-1R signaling but not NO pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 68건의 관련 임상이 등록되어 있습니다. 차별점: novel technique of integrating DRG stimulation using Direct Visual Placement with open lumbar or lumbosacral decompression an.
Urinary Bladder Neoplasms
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Recruiting
oncolytic virus (oHSV-GFP), each assessed using confocal microscopy a
linker governs the organelle targeting of TPP⁺-modified zinc phthalocyanine pho
novel technique of integrating DRG stimulation using Direct Visual Placement with open lumbar or lumbosacral decompression an
inhibits jejunal MMC activity via OTR-dependent mechanisms with partial involvement of GLP-1R signaling but not NO pathway
cytokine release, and suppresses neuroinflammation-associated transcriptional signatures specifically in microglia,
apoptosis and energy metabolism
biomarkers
escape, and enhanced mitochondrial dysfunction
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.